Skip to content

Serotonin: all studies

Page 185 of 400: studies 1,841 to 1,850 of 3,999, newest first. Back to the serotonin overview

Research

Efectos y metabolismo de la psilocibina: Una visión biomédica de los hongos mágicos

MINKA Revista de la Federación Iberoamericana de Psicodélicos y Enteógenos June 10, 2026 Pedro Alejandro Martínez-Pérez, Juan David Ortega-Patiño

Los hongos que contienen psilocibina han sido utilizados durante siglos por culturas mesoamericanas en rituales sagrados, donde se consideraban un puente hacia lo divino. En la actualidad, esta sustancia ha captado el interés de la ciencia moderna. Cuando se consume, la psilocibina se transforma en psilocina, su forma activa, que actúa principalmente sobre receptores de serotonina en el...

This Month in Anesthesiology

Anesthesiology June 9, 2026

21 Feasibility of a Multicomponent Protocol to Promote Dreaming during Surgical AnesthesiaImage: A. Johnson, Vivo Visuals Studio.Implementation of a treatment bundle consisting of verbal priming, propofol infusion, electroencephalography-guided titration, 10 min or longer of minimization of stimulation, and immediate dream interviews resulted in a high incidence of reported dreaming. Apart from...

DOI: 10.1097/aln.0000000000006161 (opens in new tab) Propofol Sedation Oxycodone Anesthesiology +8

One operator to rule them all: Unifying connectome harmonics, turbulence and complex harmonics in brain dynamics

bioRxiv (Cold Spring Harbor Laboratory) June 9, 2026 Morten L. Kringelbach, Gustavo Deco preprint

Abstract Brain dynamics can be described in three different convenient mathematical languages, namely connectome harmonics, turbulence and complex harmonics (CHARM). Here we demonstrate that these theoretical frameworks can be rigorously unified, under the functional calculus, as one self-adjoint operator and its single spectral measure. The connectome Laplacian carries that measure; the...

DOI: 10.64898/2026.06.05.730423 (opens in new tab) Laplace operator Operator biology Eigenfunction Harmonics +13

Intentions might matter in unexpected ways: A nuanced exploration of psychedelic intentions beyond their type

Research Square June 9, 2026 Iryana Mosina, David Luke preprint

Abstract Background . It is widely accepted that beyond the pharmacological predictors, individuals’ pre-drug mental disposition, including intentions , influences the psychedelic experience. However, is it not fully clear how intentions and outcomes relate. This study explores the intention qualities beyond classically assessed category and explicitness in association with outcomes. Methods ....

DOI: 10.21203/rs.3.rs-9966224/v1 (opens in new tab) Full text (opens in new tab) Centrality Association psychology Realisation Emotional reaction +5

Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.

Drugs June 4, 2026 Kevin F. Boehnke, Niloufar Pouyan, Jacob S. Aday

Chronic pain is common, costly, and for many, remains inadequately treated by existing pharmacologic and non-pharmacologic approaches. In parallel with growing dissatisfaction with conventional therapies, classic serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ayahuasca, N,N-dimethyltryptamine (DMT), and mescaline, administered alone or within...

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series

Frontiers in Pharmacology June 3, 2026 Burton J. Tabaac, Robin Carhart-Harris, Teresa Yung

Background: Traumatic brain injury (TBI) can result in prolonged post-concussive syndrome and chronic hypoxic-ischemic brain injury (HIBI) sequelae remains therapeutically challenging with the persistence of significant neurological and cognitive impairments. While conventional treatments often provide limited relief, emerging research explores alternative therapeutic interventions, including...

DOI: 10.3389/fphar.2026.1840956 (opens in new tab) Traumatic brain injury Mood Therapeutic effect Depression economics +6

Uso da ibogaína no tratamento da dependência química: uma revisão de literatura

DELOS Desarrollo Local Sostenible June 3, 2026 Ana Lara Mendonça, Déborah Rezende, Gabriela Alves et al.

A ibogaína é um alcaloide indólico extraído da Tabernanthe iboga, investigado por seu possível papel na redução de sintomas de abstinência, fissura e recaída em transtornos por uso de substâncias. Este estudo teve como objetivo analisar, por meio de revisão de literatura, as evidências científicas sobre eficácia, segurança, mecanismos farmacológicos e implicações ético-regulatórias do uso da...

DOI: 10.55905/rdelosv19.n81-006 (opens in new tab) Context archaeology Randomized controlled trial Perspective graphical Disease +1

Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.

The International Journal of Neuropsychopharmacology June 2, 2026 John R. Kelly, Christopher Sheridan, Patricia Iusan et al.

Classical serotonergic psychedelics, such as psilocybin, show emerging evidence of therapeutic potential across a range of mental health disorders, including depression, anxiety, and substance use disorders, with indications of transdiagnostic efficacy. While early-phase studies yielded encouraging results, recent larger-scale phase 3 trials, such as those evaluating psilocybin for...

MM120 (lysergide D-tartrate) Receptor Binding and Evaluation in the Rat Following 13-weeks of Administration

European Psychiatry June 1, 2026 J. Tripp, G. Smagin

Introduction MM120 (lysergide D-tartrate, LSD, CAS 32426-57-6) is under development as a potential treatment for generalized anxiety disorder and major depressive disorder. MM120 may elicit profound lasting psychological changes through interaction with brain 5-HT1A, 1B, 2A, 2C, 6 and 7 receptors, among others, while the complete mechanism is not clear. Objectives The study was performed to...

Desvenlafaxine vs SSRI as Lead-in Antidepressants in Intravenous Ketamine Treatment for TRD with Suicidality: A Randomised Controlled Trial Protocol

European Psychiatry June 1, 2026 P. Argitis, M. Demetriou, T. Koukouras et al.

Introduction Intravenous (IV) ketamine has demonstrated rapid antidepressant and anti-suicidal effects in treatment-resistant depression (TRD), yet interindividual variability in response remains significant. One unexplored factor is the impact of concomitant antidepressant medication during ketamine treatment. Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance...